Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients

被引：9

作者：

Ye, Fanhao ^{[1
]}

Li, Hebo ^{[1
,2
]}

Chen, Xiaoshu ^{[1
]}

Wang, Yi ^{[1
]}

Lin, Wei ^{[1
]}

Chen, Hao ^{[1
]}

Huang, Shiwei ^{[1
]}

Han, Sisi ^{[1
]}

Guan, Fanlu ^{[1
]}

Huang, Zhouqing ^{[2
,3
]}

机构：

[1] Shanghai Univ, Wenzhou Peoples Hosp, Affiliated Hosp 3, Dept Cardiol, Wenzhou, Zhejiang, Peoples R China

[2] Wenzhou Med Univ, Wenzhou, Zhejiang, Peoples R China

[3] Wenzhou Med Univ, Affiliated Hosp 1, Dept Cardiol, Wenzhou 325000, Zhejiang, Peoples R China

来源：

MEDICINE | 2022年 / 101卷 / 05期

关键词：

acute myocardial infarction; diabetes mellitus; heart failure with midrange ejection fraction; sacubitril valsartan; IMPACT;

D O I：

10.1097/MD.0000000000028729

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective to evaluate the clinical efficacy and safety of sacubitril valsartan in the treatment of heart failure (HF) with midrange ejection fraction after acute myocardial infarction (AMI) in diabetic patients. From January 2015 to July 2020, HF patients with diabetes mellitus complicated with AMI were retrospectively analyzed. According to the medication, they were divided into 2 groups, that is, sacubitril valsartan group (84 cases) and valsartan group (86 cases). Valsartan group took valsartan capsule (80 mg/capsule, Beijing Novartis Pharmaceutical Co., Ltd) 80 mg, qd, on the basis of routine treatment. On the basis of routine treatment, the sacubitril valsartan group took sacubitril valsartan sodium tablets (50 mg/tablet, Beijing Novartis Pharmaceutical Co., Ltd), the initial dose was 25 mg, bid, and gradually increased to the target dose according to the patient's blood pressure. After 12 months of treatment, the independent sample t test showed that the left ventricular end diastolic dimension in the sacubitril valsartan group was lower than that in the valsartan group [(47.26 +/- 4.71) mm vs (50.05 +/- 5.62) mm, P < .001]. The left ventricular ejection fraction in the sacubitril valsartan group was higher than that in the valsartan group [(54.76 +/- 4.24)% vs (49.28 +/- 3.74)%, P < .001]. chi(2) inspection showed that the readmission rate in the sacubitril valsartan group was lower than that in the valsartan group (7.14% vs 18.60%, P < .05). Sacubitril valsartan has good safety and tolerability in patients with diabetes mellitus complicated with AMI who have HF with midrange ejection fraction. Compared with valsartan, sacubitril valsartan can improve the left ventricular function better and reduce the readmission rate due to HF in these patients.

引用

页数：4

共 12 条

[1] Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction - The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial [J].